DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- DualityBio Inc.
- Target Recruit Count
- 440
- Registration Number
- NCT06953089
- Locations
- πΊπΈ
Research Site USA04-0, New York, New York, United States
πΊπΈResearch Site USA03-0, Charleston, South Carolina, United States
π¦πΊResearch Site AUS02-0, North Ryde BC, New South Wales, Australia
A Phase 1 Study of DB-2304 in Healthy Adults and SLE Participants
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Interventions
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- DualityBio Inc.
- Target Recruit Count
- 106
- Registration Number
- NCT06625671
- Locations
- π¦πΊ
Site AUS01-0, Melbourne, Victoria, Australia
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- DualityBio Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT06554795
- Locations
- πΊπΈ
Site USA08-0, Newport Beach, California, United States
πΊπΈSite USA06-0, Washington, D.C., District of Columbia, United States
πΊπΈSite USA02, Florida City, Florida, United States
A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- DualityBio Inc.
- Target Recruit Count
- 224
- Registration Number
- NCT06265428
- Locations
- π¨π³
015, Bengbu, Anhui, China
π¨π³016, Hefei, Anhui, China
π¨π³029, Hefei, Anhui, China
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- DualityBio Inc.
- Target Recruit Count
- 532
- Registration Number
- NCT06018337
- Locations
- πΊπΈ
Research Site 1141-0, Tucson, Arizona, United States
πΊπΈResearch Site 1114-0, Fullerton, California, United States
πΊπΈResearch Site 1107-0, Los Angeles, California, United States
A Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- DualityBio Inc.
- Target Recruit Count
- 610
- Registration Number
- NCT05914116
- Locations
- πΊπΈ
Research Site 111, Tucson, Arizona, United States
πΊπΈResearch Site 125, Los Angeles, California, United States
πΊπΈResearch Site 133, Los Angeles, California, United States
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2023-03-27
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- DualityBio Inc.
- Target Recruit Count
- 287
- Registration Number
- NCT05785741
- Locations
- πΊπΈ
University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States
πΊπΈUCLA Hematology/Oncology - Santa Monica, Santa Monica, California, United States
πΊπΈD&H Cancer Research Center LLC, Margate, Florida, United States
A Study of DB-1202 Monotherapy in Advanced Solid Tumors
- First Posted Date
- 2023-03-27
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- DualityBio Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT05785728
- Locations
- π¨π³
Fudan University Shanghai Cancer Center, Shanghai, China
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- DualityBio Inc.
- Target Recruit Count
- 1123
- Registration Number
- NCT05438329
- Locations
- πΊπΈ
Site 103, Cerritos, California, United States
πΊπΈSite 108, Los Angeles, California, United States
πΊπΈD&H Cancer Research Center Llc, Margate, Florida, United States
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- Conditions
- HER2-positive Advanced Solid Tumor
- Interventions
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- DualityBio Inc.
- Target Recruit Count
- 796
- Registration Number
- NCT05150691
- Locations
- πΊπΈ
TOI Clinical Research, Cerritos, California, United States
πΊπΈCalifornia Research Institute, Los Angeles, California, United States
πΊπΈSharp Memorial Hospital, San Diego, California, United States